Expression of galectin-1 in carcinoma-associated fibroblasts promotes gastric cancer cell invasion through upregulation of integrin β1

Cancer Science

Volumn 105, Issue 11, 2014, Pages 1402-1410

  He, Xu Jun ^a,b   Tao, Hou Quan ^b   Hu, Zhi Ming ^c   Ma, Ying Yu ^b   Xu, Ji ^b   Wang, Hui Ju ^b   Xia, Ying Jie ^b   Li, Li ^b   Fei, Bao Ying ^b   Li, Ya Qing ^b   Chen, Jian Zhong ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c Department of Urology People s Hospital of Haining   (China)

Author keywords

Carcinoma associated fibroblasts; Gal 1; Gastric cancer; Integrin 1; Invasion

Indexed keywords

BETA1 INTEGRIN; GALECTIN 1; LGALS1 PROTEIN, HUMAN;

CANCER GRADING; CANCER STAGING; FEMALE; FIBROBLAST; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETICS; HUMAN; MALE; METABOLISM; METASTASIS; MORTALITY; PATHOLOGY; STOMACH TUMOR; TUMOR CELL LINE; TUMOR INVASION; TUMOR VOLUME; UPREGULATION;

ANTIGENS, CD29; CELL LINE, TUMOR; FEMALE; FIBROBLASTS; GALECTIN 1; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; MALE; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; STOMACH NEOPLASMS; TUMOR BURDEN; UP-REGULATION;

EID: 84911444538     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12539     Document Type: Article

References (41)

1. Anderson C, Nijagal A, Kim J. Molecular markers for gastric adenocarcinoma: an update. Mol Diagn Ther 2006; 10: 345-52.
2. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010; 19: 1893-907.
3. Feng XY, Chen YB, Wang W et al. Time-varying pattern of recurrence risk for gastric cancer patients. Med Oncol 2013; 30: 514.
4. Park JM, Song KY, O JH, Kim WC, Choi MG, Park CH. Bone recurrence after curative resection of gastric cancer. Gastric Cancer 2013; 16: 362-9.
5. Desmouliere A, Darby IA, Gabbiani G. Normal and pathologic soft tissue remodeling: role of the myofibroblast, with special emphasis on liver and kidney fibrosis. Lab Invest 2003; 83: 1689-707.
6. Herrera M, Islam AB, Herrera A et al. Functional heterogeneity of cancer-associated fibroblasts from human colon tumors shows specific prognostic gene expression signature. Clin Cancer Res 2013; 19: 5914-26.
7. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392-401.
8. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004; 432: 332-7.
9. Li H, Fan X, Houghton J. Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem 2007; 101: 805-15.
10. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer 2001; 1: 46-54.
11. Dabbous MK, Haney L, Carter LM, Paul AK, Reger J. Heterogeneity of fibroblast response in host-tumor cell-cell interactions in metastatic tumors. J Cell Biochem 1987; 35: 333-44.
12. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006; 5: 1597-601.
13. Gout S, Huot J. Role of cancer microenvironment in metastasis: focus on colon cancer. Cancer Microenviron 2008; 1: 69-83.
14. Zhi K, Shen X, Zhang H, Bi J. Cancer-associated fibroblasts are positively correlated with metastatic potential of human gastric cancers. J Exp Clin Cancer Res 2010; 29: 66.
15. Bello IO, Vered M, Dayan D et al. Cancer-associated fibroblasts, a parameter of the tumor microenvironment, overcomes carcinoma-associated parameters in the prognosis of patients with mobile tongue cancer. Oral Oncol 2011; 47: 33-8.
16. Barondes SH, Castronovo V, Cooper DN et al. Galectins: a family of animal beta-galactoside-binding lectins. Cell 1994; 76: 597-8.
17. Yang RY, Rabinovich GA, Liu FT. Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 2008; 10: e17.
18. Ito K, Stannard K, Gabutero E et al. Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment. Cancer Metastasis Rev 2012; 31: 763-78.
19. Balan V, Nangia-Makker P, Raz A. Galectins as cancer biomarkers. Cancers (Basel) 2010; 2: 592-610.
20. Satelli A, Rao PS, Gupta PK, Lockman PR, Srivenugopal KS, Rao US. Varied expression and localization of multiple galectins in different cancer cell lines. Oncol Rep 2008; 19: 587-94.
21. Thijssen VL, Hulsmans S, Griffioen AW. The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells. Am J Pathol 2008; 172: 545-53.
22. Jung EJ, Moon HG, Cho BI et al. Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int J Cancer 2007; 120: 2331-8.
23. Clausse N, van den Brule F, Waltregny D, Garnier F, Castronovo V. Galectin-1 expression in prostate tumor-associated capillary endothelial cells is increased by prostate carcinoma cells and modulates heterotypic cell-cell adhesion. Angiogenesis 1999; 3: 317-25.
24. Nagy N, Legendre H, Engels O et al. Refined prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting. Cancer 2003; 97: 1849-58.
25. Bektas S, Bahadir B, Ucan BH, Ozdamar SO. CD24 and galectin-1 expressions in gastric adenocarcinoma and clinicopathologic significance. Pathol Oncol Res 2010; 16: 569-77.
26. Wu MH, Hong HC, Hong TM, Chiang WF, Jin YT, Chen YL. Targeting galectin-1 in carcinoma-associated fibroblasts inhibits oral squamous cell carcinoma metastasis by downregulating MCP-1/CCL2 expression. Clin Cancer Res 2011; 17: 1306-16.
27. Mbeunkui F, Johann DJ Jr. Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol 2009; 63: 571-82.
28. Lorusso G, Ruegg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 2008; 130: 1091-103.
29. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004; 5: 816-26.
30. Foubert P, Varner JA. Integrins in tumor angiogenesis and lymphangiogenesis. Methods Mol Biol 2012; 757: 471-86.
31. Tchaicha JH, Reyes SB, Shin J, Hossain MG, Lang FF, McCarty JH. Glioblastoma angiogenesis and tumor cell invasiveness are differentially regulated by beta8 integrin. Cancer Res 2011; 71: 6371-81.
32. Barczyk M, Carracedo S, Gullberg D. Integrins. Cell Tissue Res 2010; 339: 269-80.
33. Askari JA, Buckley PA, Mould AP, Humphries MJ. Linking integrin conformation to function. J Cell Sci 2009; 122: 165-70.
34. Wang D, Muller S, Amin AR et al. The pivotal role of integrin beta1 in metastasis of head and neck squamous cell carcinoma. Clin Cancer Res 2012; 18: 4589-99.
35. Kato H, Liao Z, Mitsios JV et al. The primacy of beta1 integrin activation in the metastatic cascade. PLoS ONE 2012; 7: e46576.
36. Lin HC, Wu CL, Chen YL, Huang JS, Wong TY, Yuan K. High-level beta1-integrin expression in a subpopulation of highly tumorigenic oral cancer cells. Clin Oral Investig 2014; 18: 1277-84.
37. Grzesiak JJ, Tran Cao HS, Burton DW et al. Knockdown of the beta(1) integrin subunit reduces primary tumor growth and inhibits pancreatic cancer metastasis. Int J Cancer 2011; 129: 2905-15.
38. Carbonell WS, DeLay M, Jahangiri A, Park CC, Aghi MK. beta1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma. Cancer Res 2013; 73: 3145-54.
39. Huang C, Park CC, Hilsenbeck SG et al. Beta1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res 2011; 13: R84.
40. Morello V, Cabodi S, Sigismund S et al. Beta1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells. Oncogene 2011; 30: 4087-96.
41. Moiseeva EP, Williams B, Goodall AH, Samani NJ. Galectin-1 interacts with beta-1 subunit of integrin. Biochem Biophys Res Commun 2003; 310: 1010-6.